## Research Article

## Activation of PPARy by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats

## Mahmoud Mansour, Elaine Coleman, John Dennis, Benson Akingbemi, Dean Schwartz, Tim Braden, Robert Judd, Eric Plaisance, Laura Ken Stewart, and Edward Morrison

Department of Anatomy, Physiology and Pharmacology, Auburn University, AL 36849, USA

Correspondence should be addressed to Mahmoud Mansour, mansoma@auburn.edu

Received 22 December 2008; Revised 17 March 2009; Accepted 29 April 2009

Recommended by Carolyn Komar

Peroxisome proliferator-activated receptor gamma (PPARy) activation decreased serum testosterone (T) in women with hyperthecosis and/or polycystic ovary syndrome and reduced the conversion of androgens to estradiol (E2) in female rats. This implies modulation of female sex steroid hormones by PPARy. It is not clear if PPARy modulates sex steroid hormones in diabetic males. Because PPARy activation by thiazolidinedione increased insulin sensitivity in type 2 diabetes, understanding the long term impact of PPARy activation on steroid sex hormones in males is critical. Our objective was to determine the effect of PPARy activation on serum and intratesticular T, luteinizing hormone (LH), follicle stimulating hormone (FSH) and E2 concentrations in male Zucker diabetic fatty (ZDF) rats treated with the PPARy agonist rosiglitazone (a thiazolidinedione). Treatment for eight weeks increased PPARy mRNA and protein in the testis and elevated serum adiponectin, an adipokine marker for PPARy activation. PPARy activation did not alter serum or intratesticular T concentrations. In contrast, serum T level but not intratesticular T was reduced by diabetes. Neither diabetes nor PPARy activation altered serum E2 or gonadotropins FSH and LH concentrations. The results suggest that activation of PPARy by rosiglitazone has no negative impact on sex hormones in male ZDF rats.

Copyright © 2009 Mahmoud Mansour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## 1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear transcription factors which belong to the steroid receptor superfamily but are not activated by steroid hormones. Three PPAR isotypes have been identified and include PPAR $\alpha$  (NR1C1), PPAR $\beta$  (NR1C2,  $\delta$ , NUC-1, fatty acid-activated receptor (FAAR)), and PPARy (NR1C3). A large number of both endogenous (natural) and exogenous (synthetic) ligands activate either a single PPAR isoform or all isoforms, albeit with different binding affinities and specificities [1]. Among the important PPARy synthetic activators are the thiazolidinediones (TZDs) drugs often used in the treatment of type 2 diabetes. These include Avandia (rosiglitazone), Actos (pioglitazone), a combination drug, Avandamet (rosiglitazone and metformin), and Rezulin (troglitazone). Troglitazone was withdrawn from the market because of idiosyncratic liver toxicity. Activation of PPAR $\gamma$  by TZDs increases insulin sensitivity and thus improves body glycemic control [2, 3].

PPARs are involved in a broad range of functions that include lipid homeostasis [2], tissue remodeling, angiogenesis, prostaglandin production [3], and steroidogenesis [4]. Additionally, PPARs also regulate inflammatory pathway by transrepression of transcription activity of proinflammatory transcription factors such as nuclear factor  $\kappa B$  (NF- $\kappa B$ ) [5]. Likewise, several data implicate PPARs in regulation of profibrotic [6–8] and oxidative stress responses in several cell types [9–11].

Support for the hypothesis that activation of PPARs, specifically PPARy, has an impact on sex steroid hormones action and/or production comes from several TZDs studies including two studies in male subjects [4, 12–22]. A study in healthy nondiabetic men showed that rosiglitazone treatment (8 mg/d for seven days) reduced the production rate of testosterone (T) and dihydrotestosterone (DHT)

[14]. Similarly, rosiglitazone treatment of obese nondiabetic Zucker rats (0.01% wt/wt food admixture equivalent to 4 mg/kg/d for 36 days) reduced DHT but did not alter serum T [22].

Multiple studies using ovarian and other cell culture models support a steroidogenic role for PPARy. First, activation of PPARy with troglitazone, a TZD insulin sensitizer and putative PPARy agonist, inhibited aromatase cytochrome P450 activity, the enzyme critical in the conversion of androgens to estradiol (E2), in human adipose tissue [15] and in ovarian granulosa cells [20]. Similarly, activation of PPARy by troglitazone in vitro cultures of human and porcine granulosa cells inhibited progesterone production [4]. Troglitazone was also reported to competitively inhibit  $3\beta$ -hydroxysteriod dehydrogenase ( $3\beta$ -HSD), the enzyme that catalyzes the conversion of pregnenolone to progesterone in the ovary [16]. Likewise, troglitazone was shown to inhibit androgen biosynthesis stimulated by combined LH and insulin in primary porcine thecal cell culture in a dose-dependent fashion [17].

In human adrenal NCI-H295R cells, an established in vitro model of steroidogenesis of the human adrenal cortex, both rosiglitazone and pioglitazone inhibited the activities of P450c17 and  $3\beta$ -HSD type II both of which are key microsomal enzymes in the biosynthesis of all steroid hormones [18]. In diabetic women with polycystic ovarian syndromes (PCOs), a condition characterized by anovulatory androgen secretion, relatively high E2, and excessive LH production [23–25], treatment with the PPAR $\gamma$  agonists rosiglitazone or pioglitazone improved insulin resistance and decreased hyperandrogenism in multiple studies (reviewed in [26–28]).

Toxicological studies showed that phthalate esters, used as plasticizers and stabilizers in several consumer products, activate PPARy [29], decrease key testicular steroidogenic enzymes [30] and reduce serum T production [31–34].

Although it is axiomatic that steroidogenic inhibition is a general characteristic of TZD compounds, involvement of PPARy and rosiglitazone in steroidogenic modulation under diabetic conditions remains unclear for several reasons. First, a study showed that the in vitro IC<sub>50</sub> for rosiglitazone steroidogenic inhibition is far beyond its recommended therapeutic dose [13]. Second, a number of studies showed that TZDs, including rosiglitazone, directly inhibit  $3\beta$ -HSDII and P450c17 steroidogenic enzymes independent of PPARy [13, 18]. Third, in the aforementioned male studies PPARy activation was not determined in parallel with sex hormone measurements. More importantly none of the research subjects used was diabetic where the steroidogenic effect of diabetes is an important component for evaluation of TZDs-PPARy activators. Finally, the treatment period used in the aforementioned male studies was short and varies between 7 and 36 days. Because of the above limitations, the objective of this study was to determine the link between relatively short term (8 weeks) activation of PPARy and the profile of T and E2 in male Zucker diabetic fatty rats (ZDFs) treated with a therapeutic dose of rosiglitazone.

## 2. Materials and Methods

2.1. Animals and Treatments. Male ZDF (fa/fa) rats and their age-matched lean controls (ZDF lean, fa/+ or +/+) were obtained from Charles River Laboratories (Indianapolis, Ind, USA) at 6 weeks of age. The (fa/fa) ZDF rats lack a functional leptin receptor and become hyperphagic and diabetic when fed a high fat diet. Rats were maintained under standard housing conditions (constant temperature of 22°C, ad libitum food and water, and 12:12 hours light/dark cycles) at an AAALAC-accredited lab animal facility at the College of Veterinary Medicine, Auburn University. Rats were housed in pairs and assigned to three groups with 8 rats per group. Lean nondiabetic group (group 1); ZDF rats randomly assigned to ZDF untreated group (group 2) and ZDF group treated with rosiglitazone (group 3). Lean rats were fed regular rat chow whereas ZDF rats in group 2 and 3 were fed Purina 5008 modified rat chow (Purina Mills, Richmond, Ind, USA). Rosiglitazone maleate (generously provided by GlaxoSmithKline, USA) was dissolved in 0.5% carboxymethylcelluose and administered daily via oral gavage at 3 mg/kg/d/rat starting at week 7 of age for 8 weeks. Rats in groups 1 and 2 received 0.5% carboxymethylcelluose vehicle. All rats were weighed and blood glucose was monitored from the tail vein weekly using an ACCU-CHEK glucose meter (Roche Diagnostics Co. Indianapolis, Ind, USA). Diabetes was confirmed by two consecutive measurements of blood glucose of >200 mg/dl. All animal procedures were approved by the Institutional Animal Care and Use Committee at Auburn University.

2.2. Necropsy and Tissue Collection. Rats were sacrificed by deep anesthesia with pentobarbital (50 mg/kg intraperitoneal, IP) followed with decapitation. Testes were excised, and sampled for histopathology, RNA extraction, and intratesticular T assay. Visceral epididymal fat and prostate were collected for use as positive sources for PPAR $\gamma$  expression in real-time PCR analysis. Tissues intended for RNA and hormone analysis were immediately frozen in liquid nitrogen and transferred to  $-80^{\circ}$ C until processing. Trunk blood was collected for serum isolation and stored at  $-30^{\circ}$ C prior to hormone analysis.

2.3. Total RNA Isolation. Total RNA was isolated using TRIzol reagent (Invitrogen-Life Technologies Inc., Carlsbad, Calif, USA), according to the manufacturer's instructions and as described previously in our laboratory [35]. Briefly, RNA concentrations were determined at 260 nm wavelength and the ratio of 260/280 was obtained using UV spectrophotometry (DU640, Beckman Coulter Fullerton, Calif, USA). RNA samples were treated with DNase (Ambion Inc.) to remove possible genomic DNA contamination and samples with 260/280 ratio of  $\geq 1.8$  were used.

2.4. Real-Time PCR and Agarose Gel Electrophoresis. Realtime PCR was used to determine expression of testicular PPARy mRNA and to quantify changes in mRNA level. Quantitative real-time PCR analysis was performed in  $25 \,\mu\text{L}$  reaction mixture containing RT<sup>2</sup> Real-Time SYBR/Fluorescein Green PCR master mix with final concentrations of 10 mM Tris-Cl, 50 mM KCL, 2.0 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, and 2.5 units of HotStart Taq DNA polymerase (Super Array Bioscience Corporation, Frederic, Md, USA). The reaction was completed with addition of  $1 \mu L$ first strand cDNA transcribed from  $2\mu g$  total RNA, and 0.2 mM RT<sup>2</sup> validated PCR primers for PPARy or GAPDH house keeping gene (Super Array Bioscience). Samples were run in 96-well PCR plates (Bio-Rad, Hercules, Calif, USA) in duplicates, and the results were normalized to GAPDH expression. The amplification protocol was set at 95°C for 15 minutes, and 40 cycles each at (95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds) followed by a melting curve determination between 55°C and 95°C to ensure detection of a single PCR product. Real-time PCR products at the end of each assay were combined for each treatment group and stored at  $-30^{\circ}$ C for viewing on agarose gel electrophoresis. Verification of PCR product was confirmed by determination of expected band size and sequence analysis as we described previously [35]. The resulting sequences were matched with previously published rat sequences in Genbank (accession number NM\_013124 for PPARy) using Chromas 2.31 software (Technelysium Pty ltd, Tewantin Qld 4565, Australia). RNA templates from white adipose tissue and prostate were used to generate standard curves for PPARy and GAPDH using 10-fold dilutions. Curves were made by plotting threshold cycle ( $C_t$  value) for each dilution versus the log of the dilution factor used. Relative differences in expression (fold increase or decrease) were calculated as described previously [36]. Pearson correlation coefficients (r values) for standard curves were between 0.98 and 0.99, and amplification efficiency was considered 100%.

2.5. Immunohistochemistry (IHC). Immunolocalization of PPARy by IHC was performed as described previously by our laboratory [35]. Briefly, cross sections from testes were fixed in 4% paraformaldehyde for 48 hours, embedded in paraffin, and cut at 5  $\mu$ m thickness. Sections were also fixed in Bouin's fixative (BioSciences) for staining with hematoxylin and eosin. Mounted sections were deparaffinized in Hemo-D (Scientific Safety Products) and hydrated in distilled water. Antigen retrieval was performed by heating in citrate buffer. Sections were incubated in 5% normal goat serum containing 2.5% BSA to reduce nonspecific staining. PPARy was detected with mouse anti-PPARy monoclonal antibody (Santa Cruz: sc7273; diluted 1:80 in blocker) and the antibody-antigen complexes were visualized with Alexa 488conjugated goat antimouse IgG (Molecular Probes). Sections were examined with a Nikon TE2000E microscope and digital images were made with an attached Retiga EX CCD digital camera (Q Imaging, Burnaby, BC, Canada).

2.6. Hormonal Assays. Total serum T (intraassay coefficient of variation (CV) was 4.3%), E2 (intraassay CV was 2.3%), and intratesticular (intraassay CV was 6%) level were determined by radioimmunoassay (RIA) using kits from Siemens Medical Solutions Diagnostics (Los Angles, Calif, USA)

according to manufacturer's instructions. For intratesticular T, 100 mg of testicular tissue was homogenized in  $500 \,\mu\text{L}$ Tris-PBS buffer (0.01 M Tris-HCl; pH 7.4) in plastic tubes. An additional 500  $\mu$ L was added and the homogenate was mixed with eight volumes of diethyl ether. The mixture was then vigorously vortexed and the aqueous phase quickly frozen in a dry ice bath (70% ethanol; dry ice). Extracts were subsequently air dried (warm bath at approximately 50°C under the hood) and samples were subsequently resuspended in 500 µL PBS-buffer. 50 µL of 1:10 diluted sample were used in the COAT-A-COUNT radioimmunoassay and counted in a Cobra D5005-gamma counter (Packard Instrument Co., Downers Grove, Il, USA). All samples were quantified in duplicates in a single assay. FSH and LH were determined by radioimmunoassay at the Endocrine Laboratory, Fort Collins, Colorado State University.

2.7. Serum Adiponectin. Total serum adiponectin concentration was assayed using a sandwich ELISA method (Millipore Corporation, Billerica, Mass, USA) per manufacturer's instructions. The intraassay CV was 1.1% to 1.3%.

2.8. Statistical Analysis. Analysis of real-time PCR data was performed using a modification of the delta delta  $C_t$ method ( $\Delta\Delta C_t$ ).  $\Delta C_t$  calculated from real-time PCR data were subjected to analyses of variance using Sigma Stat statistical software (Jandel Scientific, Chicago, IL). Hormonal data were subjected to analysis of variance. Treatment groups with means significantly different (P < .05) from controls were identified using Dunnett's test. When data were not distributed normally, or heterogeneity of variance was identified, analyses were performed on transformed data or ranked data.

#### 3. Results

3.1. Blood Glucose and Body Weight. The ZDF rats fed Purina 5008 high fat diet in groups 2 and 3 became diabetic by week 7 of age. By week 15 of age the mean blood glucose concentration, determined shortly before necropsy, was >600 mg/dl (above glucose meter range) in ZDF-untreated controls (group 2) versus  $123 \pm 1.7$  mg/dl in lean nondiabetic controls (group 1) and  $163.6 \pm 17.7$  in ZDF rats treated with rosiglitazone (group 3). Rats in all three experimental groups gained weight over time irrespective of treatment. The ZDF-untreated rats mean body weight at week 15 was not significantly different from lean nondiabetic (382.75  $\pm$  10.94 versus 365  $\pm$  8.2 gm, resp.; P > .05). In contrast, the mean body weight of ZDF treated rats (group 3) was more than 40% above that of ZDF untreated rats at week 15 (638.6  $\pm$  14.67 versus 382.75  $\pm$  10.9 gm, P < .001).

3.2. Serum Adiponectin. Serum adiponectin was determined to confirm PPAR $\gamma$  activation [37]. As expected, treatment with rosiglitazone increased serum adiponectin significantly in ZDF-treated compared with ZDF-untreated rats (46.33  $\pm$  2.83 versus 12.71  $\pm$  0.69 µg/mL, *P* < .001) or lean nondiabetic




FIGURE 1: (a) Real-time PCR analysis of testicular PPAR $\gamma$  mRNA levels in lean nondiabetic controls (*Lean C*), Zucker diabetic fatty (ZDF) untreated (*Diabetic U*), and ZDF rats treated with rosiglitazone (*Diabetic T*). Data are expressed as mean ± SE. n = 8 per group, \*P < .05. (b) Agarose gel (2%) showing real-time PCR products generated in (a). Lane 1, DNA markers, lanes 2-3, RNA templates (instead of cDNA) from fat (-VF) and prostate (-VPr) as negative controls. Lanes 4-5, fat from untreated rats (FU) and prostate (Pr) as positive controls. Lanes 6–9, testicular PCR products from RNA negative controls (-VT), *diabetic treated* (*DT*), *Diabetic untreated* (*DU*), and *lean untreated* (*LU*) rats. Lane 10, fat from ZDF-treated rats (FT). (c) Representative IHC of PPAR $\gamma$  protein in the testis of DT (panel 2a with insert box magnified in 2b), DU (panel 3), and LU rats (panel 4). Panel 1, -VT = negative control testis section (minus primary antibody. Arrows indicate PPAR $\gamma$  localization in spermatogonia and in Leydig cells.

untreated rats (46.33 ± 2.83 versus  $17.13 \pm 0.95 \,\mu$ g/mL, *P* < .001). In contrast, adiponectin was significantly reduced by diabetes in ZDF-untreated compared with lean nondiabetic rats ( $17.13 \pm 0.95$  versus  $12.71 \pm 0.69 \,\mu$ g/mL, *P* < .05).

3.3. Real-Time PCR, Agarose Gel Electrophoresis and IHC. Real-time PCR data showed that PPARy mRNA was expressed in the testis and was upregulated by more than two folds with rosiglitazone treatment (Figures 1(a) and 1(b)). As shown in the IHC data (Figure 1(c)) PPARy protein was specifically localized in Leydig cells located in the interstitial space between the seminiferous tubules and in spermatocytes within the inside of seminiferous tubules basement membranes.

3.4. Testicular Morphology and Histopathology. Detachment and disorganization of germ cells was evident in ZDFuntreated rats but there was no significant changes in the overall morphology of seminiferous tubules (Figure 2). Likewise, treatment did not alter seminiferous tubules morphology but desirably reversed germ cells sloughing (ZDFtreated in panel 2 versus ZDF-untreated in panel 3).

3.5. Serum and Intratesticular T. Total serum and intratesticular T were not significantly altered by PPARy activation in the testis (ZDF-treated versus ZDF-untreated, P > .05) (Figures 3 and 4). As expected total serum T was significantly lowered by diabetes (ZDF-untreated or treated versus lean nondiabetic, P < .05) (Figure 3). Surprisingly, the significant reduction in total serum T in diabetic rats was not associated with a corresponding significant reduction in intratesticular T production (Figure 4). A trend toward lower intratesticular T in ZDF versus lean rats was apparent irrespective of rosiglitazone treatment.

*3.6. Serum E2.* Neither diabetes nor PPAR*y* activation with rosiglitazone adversely altered serum E2 (Figure 5).




FIGURE 2: Representative photomicrographs of hematoxylin-eosin-stained sections of testis of nondiabetic Zucker lean control (*Lean C*, panel 1), Zucker diabetic fatty (ZDF) untreated (*Diabetic U*, panel 2), and ZDF rats treated with rosiglitazone (*Diabetic T*, panel 3). Arrows indicate germ cells strewn in the lumen of seminiferous tubules.




FIGURE 3: Serum T level in Zucker lean nondiabetic controls (*Lean C*), Zucker diabetic fatty- (ZDF-) untreated (*Diabetic U*), and ZDF rats treated with rosiglitazone (*Diabetic T*). Data are expressed as means  $\pm$  SE. n = 8 per group. \*P < .05.




FIGURE 5: Serum E2 level in Zucker lean nondiabetic controls (*Lean C*), Zucker diabetic fatty- (ZDF-) untreated (*Diabetic U*), and ZDF rats treated with rosiglitazone (*Diabetic T*). n = 6 per group. Data are expressed as means  $\pm$  SE.




FIGURE 4: Intratesticular T level in Zucker lean nondiabetic controls (*Lean C*), Zucker diabetic fatty- (ZDF-) untreated (*Diabetic U*), and ZDF rats treated with rosiglitazone (*Diabetic T*). n = 8 per group. Data are expressed as means  $\pm$  SE.

3.7. Serum FSH and LH. Serum FSH and LH were not significantly altered by activation of PPARy with rosiglitazone and/or by diabetes (P > .05). The ZDF-untreated rats, however, showed a trend for lower FSH and LH (ZDF-untreated versus lean nondiabetic) and treatment with rosiglitazone reversed this tendency (ZDF-treated versus ZDF-untreated rats) (Figures 6(a) and 6(b)).

### 4. Discussion

Rosiglitazone and other TZDs were shown to decrease hyperandrogenemia in women with PCOs and repress major steriodogenic enzymes (reviewed in [26]). Although the in vitro steroidogenic repression potency of rosiglitazone was ranked intermediate between troglitazone and pioglitazone [13], its in vivo impact on sex steroids in diabetic subjects was unknown. Specifically, information on how changes in serum steroids in male diabetic subjects relate to changes in PPARy activity was lacking. This study documents the link between testicular PPARy activation with the antidiabetic drug rosiglitazone and male sex hormone profile under diabetic conditions. Daily oral gavage of ZDF rats with rosiglitazone activated PPARy in the testis and normalized testicular germ cell derangement seen in diabetic testis. The stimulation of systemic and testicular PPARy activity by rosiglitazone, however, did not significantly alter the concentrations of gonadotropins LH and FSH, sex steroid T (both total serum and intratesticular) or serum E2.

Systemic activation of PPARy in this study was evident by the reversal of hyperglycemia, increased serum adipocytokine adiponectin, and by weight gain in ZDF-treated

5 0.5 4 0.4 Serum FSH level (ng/ml) Serum LH level (ng/ml) 0.3 3 2 0.2 1 0.1 0 0 Diabetic U Diabetic U Diabetic T Lean C Diabetic T Lean C Treatment Treatment (a) (b)

FIGURE 6: Serum FSH (a) and LH (b) in Zucker lean nondiabetic controls (*Lean C*), Zucker diabetic fatty- (ZDF-) untreated (*Diabetic U*), and ZDF rats treated with rosiglitazone (*Diabetic T*). n = 7-8 per group. Data are expressed as means  $\pm$  SE.

rats. These effects are considered biological signatures for rosiglitazone-induced PPARy activation in typically body fat depots [38, 39]. Specific activation of testicular PPARy shown here is consistent with other unrelated studies that showed the presence of this receptor in rat testis [40] and its modulation by synthetic chemicals such as phthalate esters [34, 41, 42]. Because PPARy can also be activated by endogenous ligands such as polyunsaturated fatty acids from diet sources and by metabolites of arachidonic acid [43], contribution of these ligands to the observed up regulation of testicular PPARy mRNA and protein in ZDF-treated rats could not be ruled out.

Compared to nondiabetic lean rats, ZDF-untreated rats showed consistent structural disorganization of germinal epithelium evident by abnormal accumulation of germ cells in the lumen of seminiferous tubules. This effect likely resulted from diabetes-induced oxidative stress previously recognized in diabetic rat testis [44]. Interestingly, the positive staining of germ cells for PPARy protein in IHC data suggests that rosiglitazone crosses the blood-testis barrier to enter the adluminal compartment of the seminiferous tubules resulting in activation of PPARy and reversal of germ cell sloughing. This novel effect is possibly mediated by the reported functional property of PPARy to ameliorate oxidative stress [11].

As previously known [45], diabetes in this study significantly lowered serum T. Rosiglitazone treatment, however, neither restored nor reduced serum T in ZDF-treated rats. Paradoxically, the diabetes-induced reduction in serum T in ZDF-treated and untreated rats were not associated with a corresponding significant drop in intratesticular T production, or androgen receptor expression (data not shown). Although unexpected, this finding was consistent with the nonsignificant changes observed in serum LH concentration. The unaltered intratesticular T production contrasted with significantly lowered serum T concentration may reflect a reduction in sex hormone binding globulin (SHBG) essential for T transportation in blood [46]. Reagents for determination of rat SHBG are not currently available and attempts to quantify rat SHBG using a human ELISA kit were not successful because of reagents incompatibility.

Rosiglitazone treatment reversed obesity-induced reduction of T intermediate steroid hormone precursor 17hydroxyprogesterone in the genetically related obese but nondiabetic Zucker rats [22]. In the same study, however, rosiglitazone treatment did not alter total serum T. Compared with the above findings the data in our study allow for differentiation of diabetes steroidogenic effects (ZDFuntreated versus lean nondiabetic rats) from those of PPARy activation (ZDF-treated versus ZDF-untreated rats) but does not permit a way for separation of obesity effects from those of diabetes. The lack of significant change in total serum T in the above study was nevertheless consistent with our findings. In both the aforementioned and our study a tendency toward lowered serum T production was observed in ZDF and Zucker obese versus lean littermates irrespective of treatment. A normal transient T reduction was reported in 2-4 months old Zucker obese rats [47]. The age of rats at the point of serum collection in this study was 3.75 months and thus the lowered T observed in the ZDF versus lean rats could be a reflection of the above observation in these two genetically related rat models.

Studies that support a steroidogenic regulatory role for PPARy in women treated with TZDs and in vitro ovarian cell culture models have produced contrasting results as outlined in several reviews [1, 21, 26, 27]. While some in vitro studies showed that rosiglitazone and other TZDs such as troglitazone could inhibit steroidogenic enzymes independent of PPARy activation [4, 13, 16–18, 20], an inhibitory effect of rosiglitazone was not reflected in total T and E2 concentrations in ZDF-treated rats in our study. In summary, our data show that PPARy activation with rosiglitazone for eight weeks had no negative impact on total sex hormone concentrations in diabetic male rats. This

finding is firmly in line with studies that showed strong TZD-PPARy activation [48, 49] but weaker in vitro steroidogenic inhibitory effects of rosiglitazone [13].

### Acknowledgments

This work was partly supported by Title VI intramural Auburn University grant to M. Mansour, and Diabetes Trust Foundation grant to Elaine Coleman.

### References

- C. M. Komar, "Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling," *Reproductive Biology and Endocrinology*, vol. 3, article 41, pp. 1–14, 2005.
- [2] R. M. Evans, G. D. Barish, and Y.-X. Wang, "PPARs and the complex journey to obesity," *Nature Medicine*, vol. 10, no. 4, pp. 355–361, 2004.
- [3] B. Desvergne and W. Wahli, "Peroxisome proliferatoractivated receptors: nuclear control of metabolism," *Endocrine Reviews*, vol. 20, no. 5, pp. 649–688, 1999.
- [4] S. Gasic, Y. Bodenburg, M. Nagamani, A. Green, and R. J. Urban, "Troglitazone inhibits progesterone production in porcine granulosa cells," *Endocrinology*, vol. 139, no. 12, pp. 4962–4966, 1998.
- [5] L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, "Peroxisome proliferator-activated receptors and inflammation," *Pharmacology & Therapeutics*, vol. 110, no. 3, pp. 371–385, 2006.
- [6] M. Wu, D. S. Melichian, E. Chang, M. Warner-Blankenship, A. K. Ghosh, and J. Varga, "Rosiglitazone abrogates bleomycininduced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-y," *The American Journal of Pathology*, vol. 174, no. 2, pp. 519–533, 2009.
- [7] J. E. Milam, V. G. Keshamouni, S. H. Phan, et al., "PPAR-y agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis," *American Journal of Physiology*, vol. 294, no. 5, pp. L891–L901, 2008.
- [8] T. Kawai, T. Masaki, S. Doi, et al., "PPAR-y agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β," *Laboratory Investigation*, vol. 89, no. 1, pp. 47–58, 2009.
- [9] S. S. Chung, M. Kim, B.-S. Youn, et al., "Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor *y* in human skeletal muscle cells," *Molecular and Cellular Biology*, vol. 29, no. 1, pp. 20–30, 2009.
- [10] E. Teissier, A. Nohara, G. Chinetti, et al., "Peroxisome proliferator-activated receptor  $\alpha$  induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR- $\alpha$  activation properties," *Circulation Research*, vol. 95, no. 12, pp. 1174–1182, 2004.
- [11] P. R. Devchand, O. Ziouzenkova, and J. Plutzky, "Oxidative stress and peroxisome proliferator-activated receptors. Reversing the curse?" *Circulation Research*, vol. 95, no. 12, pp. 1137– 1139, 2004.
- [12] P. D. Schoppee, J. C. Garmey, and J. D. Veldhuis, "Putative activation of the peroxisome proliferator-activated receptor y impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells," *Biology of Reproduction*, vol. 66, no. 1, pp. 190–198, 2002.

- [13] W. Arlt, R. J. Auchus, and W. L. Miller, "Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and  $3\beta$ -hydroxysteroid dehydrogenase," *The Journal of Biological Chemistry*, vol. 276, no. 20, pp. 16767–16771, 2001.
- [14] H. Vierhapper, P. Nowontny, and W. Waldhäusl, "Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone," *Metabolism: Clinical and Experimental*, vol. 52, no. 2, pp. 230–232, 2003.
- [15] G. L. Rubin, J. H. Duong, C. D. Clyne, et al., "Ligands for the peroxisomal proliferator-activated receptor *y* and the retinoid X receptor inhibit aromatase cytochrome P450 (*CYP19*) expression mediated by promoter II in human breast adipose," *Endocrinology*, vol. 143, no. 8, pp. 2863–2871, 2002.
- [16] S. Gasic, M. Nagamani, A. Green, and R. J. Urban, "Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary," *American Journal of Obstetrics & Gynecology*, vol. 184, no. 4, pp. 575–579, 2001.
- [17] J. D. Veldhuis, G. Zhang, and J. C. Garmey, "Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of *de novo* androgen biosynthesis by thecal cells in vitro," *The Journal of Clinical Endocrinol*ogy & Metabolism, vol. 87, no. 3, pp. 1129–1133, 2002.
- [18] P. Kempná, G. Hofer, P. E. Mullis, and C. E. Flück, "Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2," *Molecular Pharmacology*, vol. 71, no. 3, pp. 787–798, 2007.
- [19] A. Dunaif, D. Scott, D. Finegood, B. Quintana, and R. Whitcomb, "The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome," *The Journal of Clinical Endocrinology & Metabolism*, vol. 81, no. 9, pp. 3299–3306, 1996.
- [20] Y.-M. Mu, T. Yanase, Y. Nishi, et al., "Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells," *Biochemical and Biophysical Research Communications*, vol. 271, no. 3, pp. 710–713, 2000.
- [21] C. E. Minge, R. L. Robker, and R. J. Norman, "PPAR gamma: coordinating metabolic and immune contributions to female fertility," *PPAR Research*, vol. 2008, Article ID 243791, 19 pages, 2008.
- [22] C. Fürnsinn, P. Nowotny, B. Brunmair, et al., "Thiazolidinediones influence plasma steroids of male obese Zucker rats," *Endocrinology*, vol. 143, no. 1, pp. 327–330, 2002.
- [23] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome," *Fertility and Sterility*, vol. 81, no. 1, pp. 19–25, 2004.
- [24] A. Dunaif, "Adrenal disorders and polycystic ovary syndrome," *Hormone Research*, vol. 37, supplement 3, pp. 39–44, 1992.
- [25] S. Franks, "Polycystic ovary syndrome," *The New England Journal of Medicine*, vol. 333, no. 13, pp. 853–861, 1995.
- [26] B. Toth, D. Hornung, C. Scholz, S. Djalali, K. Friese, and U. Jeschke, "Peroxisome proliferator-activated receptors: new players in the field of reproduction," *American Journal of Reproductive Immunology*, vol. 58, no. 3, pp. 289–310, 2007.
- [27] P. Froment, F. Gizard, D. Defever, B. Staels, J. Dupont, and P. Monget, "Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition," *Journal of Endocrinology*, vol. 189, no. 2, pp. 199–209, 2006.
- [28] A. Dunaif, "Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal," *Nature Reviews Endocrinology*, vol. 4, no. 5, pp. 272–283, 2008.

- [29] J. N. Feige, L. Gelman, D. Rossi, et al., "The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor *y* modulator that promotes adipogenesis," *The Journal of Biological Chemistry*, vol. 282, no. 26, pp. 19152–19166, 2007.
- [30] N. J. Barlow, S. L. Phillips, D. G. Wallace, M. Sar, K. W. Gaido, and P. M. D. Foster, "Quantitative changes in gene expression in fetal rat testes following exposure to di(*n*-butyl) phthalate," *Toxicological Sciences*, vol. 73, no. 2, pp. 431–441, 2003.
- [31] K. P. Lehmann, S. Phillips, M. Sar, P. M. D. Foster, and K. W. Gaido, "Dose-dependent alterations in gene expression and testosterone synthesis in the fetal testes of male rats exposed to di(*n*-butyl) phthalate," *Toxicological Sciences*, vol. 81, no. 1, pp. 60–68, 2004.
- [32] C. J. Thompson, S. M. Ross, and K. W. Gaido, "Di(*n*-butyl) phthalate impairs cholesterol transport and steroidogenesis in the fetal rat testis through a rapid and reversible mechanism," *Endocrinology*, vol. 145, no. 3, pp. 1227–1237, 2004.
- [33] J. Borch, M. Axelstad, A. M. Vinggaard, and M. Dalgaard, "Diisobutyl phthalate has comparable anti-androgenic effects to di-*n*-butyl phthalate in fetal rat testis," *Toxicology Letters*, vol. 163, no. 3, pp. 183–190, 2006.
- [34] J. Borch, S. B. Metzdorff, A. M. Vinggaard, L. Brokken, and M. Dalgaard, "Mechanisms underlying the anti-androgenic effects of diethylhexyl phthalate in fetal rat testis," *Toxicology*, vol. 223, no. 1-2, pp. 144–155, 2006.
- [35] M. M. Mansour, H. O. Goyal, T. D. Braden, et al., "Activation of penile proadipogenic peroxisome proliferator-activated receptor *y* with an estrogen: interaction with estrogen receptor alpha during postnatal development," *PPAR Research*, vol. 2008, Article ID 651419, 10 pages, 2008.
- [36] J. Vandesompele, K. De Preter, F. Pattyn, et al., "Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes," *Genome Biology*, vol. 3, no. 7, article research0034.1-0034.11, pp. 1–12, 2002.
- [37] J. E. Caminos, R. Nogueiras, F. Gaytán, et al., "Novel expression and direct effects of adiponectin in the rat testis," *Endocrinology*, vol. 149, no. 7, pp. 3390–3402, 2008.
- [38] M. Gurnell, "Peroxisome proliferator-activated receptor y and the regulation of adipocyte function: lessons from human genetic studies," *Best Practice & Research Clinical Endocrinol*ogy & Metabolism, vol. 19, no. 4, pp. 501–523, 2005.
- [39] R. M. Evans, G. D. Barish, and Y.-X. Wang, "PPARs and the complex journey to obesity," *Nature Medicine*, vol. 10, no. 4, pp. 355–361, 2004.
- [40] O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, "Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat," *Endocrinology*, vol. 137, no. 1, pp. 354–366, 1996.
- [41] N. Bhattacharya, J. M. Dufour, M.-N. Vo, J. Okita, R. Okita, and K. H. Kim, "Differential effects of phthalates on the testis and the liver," *Biology of Reproduction*, vol. 72, no. 3, pp. 745– 754, 2005.
- [42] J. Y. Ryu, B. M. Lee, S. Kacew, and H. S. Kim, "Identification of differentially expressed genes in the testis of Sprague-Dawley rats treated with di(*n*-butyl) phthalate," *Toxicology*, vol. 234, no. 1-2, pp. 103–112, 2007.
- [43] S. A. Kliewer, S. S. Sundseth, S. A. Jones, et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 9, pp. 4318–4323, 1997.

- [44] B. Shrilatha and Muralidhara, "Early oxidative stress in testis and epididymal sperm in streptozotocin-induced diabetic mice: its progression and genotoxic consequences," *Reproductive Toxicology*, vol. 23, no. 4, pp. 578–587, 2007.
- [45] J. B. Farrell, A. Deshmukh, and A. A. Baghaie, "Low testosterone and the association with type 2 diabetes," *The Diabetes Educator*, vol. 34, no. 5, pp. 799–806, 2008.
- [46] G. L. Hammond, "Extracellular steroidbinding proteins," in *Steroid Hormone Action*, Frontiers in Molecular Biology, pp. 1–25, IRL Press at Oxford University, Oxford, UK, 1993.
- [47] R. A. Young, R. Frink, and C. Longcope, "Serum testosterone and gonadotropins in the genetically obese male Zucker rat," *Endocrinology*, vol. 111, no. 3, pp. 977–981, 1982.
- [48] G. Berger, P. Bailey, C. Biswas, et al., "Thiazolidinediones produce a conformational change in peroxisomal proliferatoractivated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice," *Endocrinology*, vol. 137, no. 10, pp. 4189–4195, 1996.
- [49] T. M. Willson, J. E. Cobb, D. J. Cowan, et al., "The structureactivity relationship between peroxisome proliferatoractivated receptor *y* agonism and the antihyperglycemic activity of thiazolidinediones," *Journal of Medicinal Chemistry*, vol. 39, no. 3, pp. 665–668, 1996.

# Special Issue on PPARs and Anticancer Therapies

## **Call for Papers**

With ongoing improvements in cancer therapy and health care, the population of long-term cancer survivors continues to grow; 62% of adult and 75% of pediatric cancer patients survive beyond 5 years. For this ever-growing population, late effects of anticancer therapy remain a significant risk. For example, a growing body of evidence suggests that inflammatory responses play a critical role in the pathogenic mechanisms involved in the development and progression of radiation-induced late effects. In this regard, recent studies suggest that PPARs, potent mediators of anti-inflammatory responses, may represent a novel therapeutic target to ameliorate or prevent radiation-induced normal tissue injury. Moreover, PPAR agonists appear to exhibit antitumor effects, offering the promise of increasing the therapeutic ratio for cancer patients, enhancing both their quality of life and longterm survival. More potent antitumor drug combinations are urgently needed for clinical cancer trials. Exciting studies have shown synergistic antitumor activity between PPARy ligands and chemotherapeutic agents. Similarly, the combinations of PPARa ligands and PPARy ligands have shown preclinical antitumor activity in experimental animal models. Due to the efficacy and commercial availability of these agents, they are ideally suited for clinical trials.

We invite authors to present original research articles or reviews that address any aspect of PPARs and anticancer therapeutic approaches. Potential topics include but are not limited to:

- Role of PPARs in radiation- and/or chemotherapyinduced normal tissue injury
- Modulation of anticancer therapy-mediated normal tissue injury using PPAR agonists
- Antitumor properties of PPARs, alone or in combination with radiation and/or chemotherapeutic drugs
- Pharmacokinetic interactions between anticancer therapies and PPAR modulators

Before submission, authors should carefully read over the journal's Author Guidelines, which are located at http://www .hindawi.com/journals/ppar/guidelines.html. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/, according to the following timetable:

Manuscript Due	July 1, 2009
First Round of Reviews	October 1, 2009
Publication Date	January 1, 2010

#### Lead Guest Editor

**Michael E. C. Robbins,** Robbins Laboratory, Section of Radiation Biology, The Department of Radiation Oncology, Wake Forest University School of Medicine, NC 27157, USA; mrobbins@wfubmc.edu

### **Guest Editors**

**Christine Linard,** Institute for Radioprotection and Nuclear Safety, 92262 Fontenay aux Roses Cedex, France; christine.linard@irsn.fr

**Dipak Panigrahy,** Children's Hospital, Harvard Medical Center, Boston, MA 02115, USA; dipak.panigrahy@childrens.harvard.edu

Hindawi Publishing Corporation http://www.hindawi.com

## Special Issue on PPARs and Hypertension

## **Call for Papers**

Hypertension is a major public health problem, affecting 1 in 4 American adults. The majority of the cases are unexplained and often classified as essential hypertension. Emerging evidence suggests that as much as 65-75% of the risk for essential hypertension is attributable to obesity and overweight. There is an urgent need to understand the molecular basis of obesity-associated hypertension and also to develop effective therapies. Both clinical and animal studies have demonstrated that the thiazolidinedione (TZD) PPARy ligands exert blood pressure lowering effects independent of their insulin sensitizing action. Interestingly, TZD-induced hypotension occurs despite the expansion of plasma volume. PPAR $\alpha$  agonists can also exhibit similar beneficial effects on hypertension. Together, different PPAR subtypes may serve as novel targets for development of antihypertensive therapies and may also offer a unique opportunity to investigate the molecular mechanisms that link energy metabolism and blood pressure regulation.

We invite authors to present original research articles or reviews that address any aspect of PPARs and hypertension. Potential topics include but are not limited to:

- Antihypertensive effects of PPAR agonists in patients and animals
- Role of PPARs in regulation of cardiovascular and renal functions
- Role of PPARs in regulation of sympathetic nerve activity
- Role of PPARs in regulation of fluid and electrolyte metabolism
- Role of PPARs in regulation of inflammatory response and tissue remodeling
- Interaction between PPARs and the renin-angiotensin system
- Role of PPARs in pulmonary hypertension
- Role of RXRs in blood pressure regulation

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www .hindawi.com/journals/ppar/guidelines.html. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Manu	iscript Due	September 1, 2009
First	Round of Reviews	December 1, 2009
Publi	cation Date	March 1, 2010

### **Guest Editors**

**Tianxin Yang,** School of Medicine, The University of Utah, Salt Lake City, UT 84132, USA; tianxin.yang@hsc.utah.edu

**Frank C. Brosius,** Nephrology Division, Department of Internal Medicine, University of Michigan Health Center, Ann Arbor, MI 48109, USA; fbrosius@umich.edu

**Willa A. Hsueh,** Methodist Hospital Research Institute, Houston, TX 77030, USA; wahsueh@tmhs.org

Hindawi Publishing Corporation http://www.hindawi.com

# Special Issue on PPARs, RXRs, and Drug-Metabolizing Enzymes

## **Call for Papers**

Numerous studies have implicated PPAR/RXR activation of drug metabolizing enzymes in both drug efficacy and druginduced idiosyncrasies. Studies suggest that modulation of PPAR $\alpha$ , PPAR $\delta$ , and PPAR $\gamma$  induction of drug-metabolizing enzymes, especially cytochrome P450, results in altered pharmacokinetics and/or pharmacodynamics impacting drug therapeutic efficacy and/or adverse drug reactions.

A more comprehensive understanding of how different PPARs and RXRs interact to regulate the phase I, phase II, and phase III enzymes may provide significant insight into the rational choice of drug combinations that offer the best therapeutic outcome.

The purpose of this special issue of *PPAR Research* is to give authors an opportunity to present original research articles and reviews addressing all aspects of PPAR biology related to drug metabolism, drug efficacy, adverse drug reaction, and the biology, pharmacology, and therapeutic use of PPAR and RXR agonists. Potential topics include (but are not limited to):

- Regulation of phase I drug-metabolizing enzymes by PPAR and RXR agonists
- Novel agonists and antagonists of PPAR and RXR function in the drug metabolism
- Control of phase II conjugating enzymes in drug metabolism
- Exploring drug metabolism with humanized and PPAR knockout mice
- Regulation of cholesterol and bile acid metabolism by PPAR and RXR agonists
- Phase III ABC drug transporter regulation by PPAR
- Metabolomics: *metabolic profiling* of PPAR and RXR agonists
- PPAR agonist and antagonist in human and rodent chemically induced toxicity
- Control of ethanol metabolism by PPARs and RXRs in alcoholic liver disease
- Clinical aspects of PPAR and RXR agonists in adverse drug reactions
- Pharmacogenomics of PPARs in the human population with regard to the regulation of drugmetabolizing enzymes in adverse drug reaction and gender-specific role in personalized medicine

Authors should follow the PPAR Research manuscript format described at http://www.hindawi.com/journals/ppar/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Manuscript Due	May 1, 2009
First Round of Reviews	August 1, 2009
Publication Date	November 1, 2009

#### **Guest Editors**

James P. Hardwick, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272-0095, USA; jph@neoucom.edu

John Y. L. Chiang, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272-0095, USA; jchiang@neoucom.edu

Hindawi Publishing Corporation http://www.hindawi.com